Key Takeaways
- DSO offers often quote headline EBITDA multiples that overstate actual cash received at closing, with the balance tied to earnouts, rollover equity, and holdbacks.
- Post-close employment agreements frequently include production targets and clawback provisions that can reduce realized value if performance dips.
- Rolled equity in DSO deals is illiquid and carries meaningful risk, with payouts dependent on future recapitalization events that may be delayed.
- Without competitive tension or independent valuation, sellers negotiating directly with one DSO are likely to receive lower offers than those who run a structured process.
- McLerran & Associates helps owners narrow the information gap by running a competitive, sell-side process that quantifies real after-tax outcomes across both DSO and private-buyer paths. Schedule a confidential call to review your options before any offer is made.
How DSO Earn-Outs Typically Work
A DSO earn-out is a contingent payment, meaning the seller receives this money after closing only if specific performance targets are met. In a typical dental DSO transaction, immediate cash at close represents just a portion of the stated valuation. The remaining value is split across an earnout, rollover equity, and an escrow holdback. Rollover equity is an ownership stake in the acquiring DSO platform. An escrow holdback is a portion of the purchase price held in reserve to cover post-close adjustments. Each component has its own timeline, conditions, and risk profile, and none of that detail appears in the headline multiple.
The Information Asymmetry in DSO Negotiations
A practice owner usually sells once in a career. A DSO acquisition team closes deals every week. That imbalance shapes every part of the negotiation. It affects how EBITDA is calculated, how earnout targets are written, and which line items end up in the small print of the employment agreement. EBITDA means earnings before interest, taxes, depreciation, and amortization, and it is the profitability metric DSOs use to set valuations.
An unrepresented dentist negotiating directly with a single DSO has no competitive tension, no independent valuation, and no benchmark for what the broader market might pay. DSO opening offers often sit below best-and-final pricing on practices that later enter multi-bid processes. The first number on the table is rarely the number that reflects full market interest.
McLerran & Associates exists to narrow this gap. As a dental-only sell-side advisor with more than 10,000 practices evaluated and roughly $2 billion in closed transaction volume, the firm helps control the narrative around a practice’s value and runs the deal on the owner’s behalf.
Find out where your practice stands before any DSO conversation begins.
Headline Multiple vs. Realized Cash at Closing
The Reddit complaint about a “dangled multiple” has a clear financial explanation. A DSO may quote a 6x EBITDA multiple, but that figure describes the total stated valuation, not the cash the seller receives at closing. In many DSO offers, immediate cash at close equals roughly half the stated valuation. The balance is tied to an earnout and rollover equity that may or may not fully pay out.
Holdbacks widen this gap. Holdbacks in dental deals often represent a meaningful portion of the purchase price and remain in place for several years. This structure creates a delay between signing and receiving full proceeds. Across lower-middle-market deals, a significant percentage experience a post-LOI price adjustment during due diligence, so the agreed number often moves downward before closing.
Realized value works better as a formula: cash at close, plus likely escrow recovery, plus risk-adjusted earnout and rollover value. The headline multiple alone does not tell that story. McLerran’s financial forecasting models this picture, projecting after-tax proceeds across different deal structures and 3, 5, 7, and 10-year timelines so owners can compare real outcomes rather than marketing numbers.
Work-Back Period and Production Targets in Employment Terms
Beyond the headline valuation gap, the post-close employment agreement introduces another layer of risk that many sellers discover too late. Reddit threads frequently describe surprise at post-close employment terms. In most DSO transactions, the selling dentist continues practicing for a defined period, often 3 to 5 years, while shifting from owner-operator to W-2 clinical employee. More DSOs now require a minimum 5-year post-close employment term to complete transactions, according to the TUSK Practice Sales Q2 2026 Dental Market Report.
Production targets embedded in these agreements can be demanding. Many DSO contracts include a production clawback. Falling below a set percentage of pre-close production can trigger repayment or a price adjustment. Monthly collections floors are often enforced at a percentage of the trailing 12-month average. Earnout realization in DSO sales can range from a portion to the full face value, with a mean for well-structured earnouts in stable portfolios. Sellers without strong evidence to the contrary may want to assume a lower realization probability.
McLerran negotiates earnout terms before the letter of intent, or LOI, is signed. The firm pushes for pro-rata provisions so a near-miss on an EBITDA target still pays most of the earnout. It also pushes for later start dates that account for integration disruption.
Equity Rollover Risk and Post-Close Culture Shift
Rolled equity, the ownership stake a seller retains in the DSO platform after closing, often becomes the part of the deal that “did not work out” in Reddit stories. The structure explains why. In healthcare deals, including dental DSO transactions, rollover equity can represent a larger portion of total consideration, which means buyers shift more risk onto sellers. That equity is illiquid. It cannot be sold until the DSO platform is recapitalized or sold to the next private equity buyer, and that timeline often runs several years.
The risk shows up in practice. Recapitalization delays tied to slower M&A activity have created a standoff between dentists expecting payouts from rolled equity and sponsors waiting for returns, according to Brian Colao, Director of the DSO Industry Group at Dykema, in a June 2026 podcast. Dentists who hold minority ownership interests in privately held DSOs receive limited financial disclosures and have fewer protections than investors in public companies. Restructuring events can significantly change the value of their equity.
Cultural change after closing can feel just as significant. After DSO affiliation, central teams often assume control of scheduling software, lab partners, materials budgets, and marketing. Owner-dentist input on operational choices usually declines, while the focus shifts to chairside work. Knowing exactly what a DSO will and will not do for a practice after closing can be as important as the headline number.
Understand Your Transition Options
The risks outlined above, from earnout clawbacks to illiquid equity to culture shifts, are often knowable and measurable before any offer is accepted. The first step in McLerran’s four-part advisory process is helping owners understand both transition pathways before committing to either. Practices generating $1.5M or more in annual revenue can often qualify for both a doctor-to-doctor sale and a DSO affiliation. The right path can depend on the owner’s goals, timeline, and practice profile, not on whichever buyer called first.
McLerran builds a side-by-side valuation that quantifies a practice’s worth in both markets, the private-buyer market and the DSO or private equity market. This approach helps owners choose with information instead of guesswork. The valuation is CPA-led, diligence-grade work done up front, so the number is built to withstand buyer scrutiny. When the valuation holds through diligence, buyers have less room to re-trade the price later.
Create Competition for Your Practice
A seller who talks to one DSO receives one offer and has no competitive tension to push the price higher. Multi-bid processes for practices in this collections range often produce final offers above the highest single-bid reference. Some outliers reach even higher on highly desirable practices.
McLerran runs a structured, auction-style bid process that typically lasts 45 to 60 days and generates multiple offers from a vetted pool of qualified buyers. DSOs known for poor post-close environments are screened out and never reach the table. This structure often results in higher valuations than owners achieve when selling on their own.
Match With the Right Buyer, Not Just the Highest Bidder
The highest bidder is not always the right buyer. A DSO deal creates a long-term partnership. The selling dentist will likely work inside that organization for years, and the staff and patients will live with the outcome. McLerran focuses on both price and fit, identifying buyers whose strategy, support model, and culture align with what the owner wants for the practice after exit.
Fit also includes treating buyers like investments. Rollover equity in a DSO acquisition represents an illiquid bet on the larger platform, with payout dependent on a future recapitalization or secondary sale at a higher multiple. That equity can shrink or disappear if the platform underperforms. McLerran helps owners review a DSO’s profitability, growth trajectory, leadership quality, and financial backing before signing.
Discuss which buyers match your practice profile in a free, confidential discovery call.
Maximize the Outcome of Your Sale
Maximizing outcome involves more than chasing the highest headline number. It includes making sure the agreed value holds through due diligence without re-trading. It also includes earnout terms that do not punish normal performance swings. Outcome quality depends on rollover equity sitting in a platform that is financially healthy enough to deliver a second payout. It also depends on understanding the after-tax proceeds across all these components before signing, not discovering them later.
McLerran provides “quality of earnings” defense through diligence. The team defends the EBITDA it underwrote when the buyer’s team reviews the numbers and reminds buyers that other vetted bidders remain available if they attempt to re-trade the deal. The firm reports a transaction close rate of roughly 85–90% among its clients, compared with an industry norm closer to 35–40%.
Reddit Claims vs. Market Reality
| Reddit Claim | What It Describes | Market Data | McLerran Mechanism |
|---|---|---|---|
| “They dangle a multiple” | Headline EBITDA multiple overstates cash received | Cash at close is frequently only a portion of stated valuation | Multi-year cash-flow modeling quantifies real after-tax proceeds across all components |
| “Small print” in the employment agreement | Production targets and clawback provisions buried in post-close terms | Falling below a certain percentage of pre-close production can trigger repayment or price adjustment | LOI negotiation pushes for pro-rata earnout provisions and non-punitive clawback language |
| “Work-back period longer than expected” | Post-close employment commitment extends years beyond what sellers anticipated | More DSOs now require a minimum 5-year post-close employment term | Employment terms negotiated before LOI; private-buyer path offers a brief work-back alternative |
| “The equity didn’t pay out” | Rolled equity remained illiquid beyond expected timeline | Recapitalization delays have created a standoff between dentists expecting payouts and sponsors waiting for returns | DSO buyers vetted for financial health; rollover equity modeled conservatively across 3-, 5-, 7-, and 10-year horizons |
| “The first offer was the only offer” | No competitive process; seller negotiated from a single-bid position | DSO opening offers run below best-and-final on practices that proceed to multi-bid processes | Structured auction process generates multiple offers in 45–60 days |
| “The deal got re-traded in diligence” | Agreed price adjusted downward after LOI was signed | A significant percentage of lower-middle-market deals experience a post-LOI price adjustment during due diligence | CPA-led, diligence-grade valuation done up front; quality-of-earnings defense through close |
| “I didn’t know what I was getting into” | Seller lacked side-by-side comparison of private-buyer vs. DSO outcomes | DSO deals involve more complex legal structures, employment agreements, and earnout provisions, while private-buyer deals are simpler and usually require only a brief 30–90 day transition period | Side-by-side valuation quantifies worth in both markets before any path is chosen |
Private-Buyer vs. DSO Paths for $1.5–3M Practices
Practices in the $1.5–3M revenue range sit in what McLerran describes as the “Venn diagram middle.” These practices can often pursue either a doctor-to-doctor sale or a DSO affiliation. The two pathways differ across several dimensions that do not compress neatly into a single comparable number, so a narrative comparison can be more helpful.
On the private-buyer path, a selling dentist usually works back for a short transition period after closing and then exits. The transaction is simpler, with no earnout, no equity rollover, and no multi-year employment agreement. Individual buyers typically offer a percentage of collections and close in 60–120 days. The proceeds are cleaner and the timeline is shorter, although the ceiling on total proceeds is often lower than a well-run DSO process for practices at this revenue level.
On the DSO path, total stated consideration can be materially higher, but the structure is more complex. DSO deals may pay the equivalent of a higher percentage of collections. A portion of the purchase price is paid in cash at closing, another portion as contingent earnouts over multiple years, and another portion as illiquid equity rollover. The post-close commitment is longer, tax treatment varies by component, and the final outcome depends partly on the DSO platform’s future performance.
Because McLerran works both paths in roughly equal measure, about a 50/50 split, it can present a true side-by-side comparison rather than steering owners toward the path that benefits the advisor. The right answer depends on the owner’s specific numbers, goals, and timeline.
Frequently Asked Questions
What is the difference between a headline multiple and realized cash in a DSO deal?
A headline multiple is the total stated valuation expressed as a multiple of EBITDA, the number a DSO uses to describe deal size. Realized cash is what the seller actually receives at each stage, and it is almost always lower than the headline figure at the time of closing. The gap exists because DSO deals typically split total consideration across three components: cash at close, an earnout paid over 2–3 years if performance targets are met, and rollover equity that remains illiquid until the DSO platform is recapitalized or sold, often 3–7 years later. Reviewing the realistic value of each component, including the probability that earnout targets will be met and the financial health of the DSO holding the equity, can be essential before evaluating any offer.
How long will I have to keep working after selling my practice to a DSO?
Post-close employment commitments in DSO transactions have lengthened in recent years. A minimum of 3–5 years is common, and some DSOs now require 5 years or more as a condition of closing. During that period, the selling dentist usually shifts from owner-operator to W-2 clinical employee, with compensation often structured as a percentage of production rather than ownership distributions. The specific terms, including days per week, production targets, clawback provisions, non-compete geography and duration, and what happens to the earnout if the employment agreement ends early, vary by deal and can be negotiated before the letter of intent is signed. In a doctor-to-doctor sale, the work-back period is typically a brief transition.
What are the risks of rolled equity in a DSO deal?
Rolled equity, the ownership stake a seller retains in the DSO platform after closing, can offer the potential for a “second bite of the apple” when the platform is later sold at a higher multiple. The risk is that this equity is illiquid, minority-position stock in a privately held company. The seller has limited visibility into the DSO’s financials, limited influence over its operations, and no ability to sell the stake until the platform’s private equity sponsor decides to recapitalize or exit. If the DSO underperforms, takes on excessive debt, or undergoes a restructuring, the value of that equity can be significantly reduced. Reviewing the DSO’s profitability, revenue growth, management team, and financial backing before accepting rolled equity can be as important as negotiating the cash-at-close figure.
Should I sell to a private buyer or a DSO?
The answer can depend on your practice’s size and profitability, your personal goals, and your timeline. Practices in the $1–1.5M revenue range often fit a doctor-to-doctor sale well. The largest practices at $3M and above often point toward the DSO path. Practices in the $1.5–3M middle can genuinely pursue either. Because the two paths differ in total proceeds, deal complexity, post-close commitment, and tax treatment, a side-by-side valuation that quantifies your practice’s worth in both markets can provide a clearer basis for choice than a single DSO’s opening offer.
What does a sell-side advisor actually do in a dental practice sale?
A sell-side advisor represents the practice owner, not the buyer, through every stage of the transaction. That work includes building a diligence-grade EBITDA valuation up front, creating a competitive bid process among vetted buyers, negotiating the letter of intent and all deal terms, defending the agreed valuation through due diligence when buyers attempt to re-trade the price, and managing the transaction to a successful close. The advisor’s role is to control the narrative around the practice’s profitability, create competitive tension that supports a stronger price, and help the owner understand the real after-tax outcome of every deal structure before signing. A dental-specific sell-side advisor also brings knowledge of which buyers are well-capitalized and well-run, and which ones to avoid.
Conclusion: How to Evaluate a DSO Offer
Reddit threads about selling dental practices to DSOs are not necessarily warnings that DSO deals are always bad. They are often warnings about information asymmetry. Many owners entered a complex, once-in-a-lifetime transaction without the tools to evaluate what they were signing. The headline multiple, the earnout structure, the work-back period, the equity rollover, and the post-close culture shift can all be examined in advance. The key question is whether the seller has the expertise and process to surface those details.
Before evaluating any offer, a premier practice owner in the $1.5M+ revenue range can benefit from working through several criteria:
- What is the practice’s true EBITDA after all legitimate add-backs are unpacked, and will that number hold under buyer scrutiny?
- What is the practice worth in both the private-buyer market and the DSO market, side by side?
- What are the realistic after-tax proceeds across all deal components, including cash at close, earnout, and equity, over a 5- to 10-year horizon?
- How financially healthy is the DSO holding the rolled equity, and what is the realistic timeline to liquidity?
- What are the exact post-close employment terms, production targets, clawback provisions, and non-compete geography?
- Has a competitive process been run to establish what the market will actually pay, not just what one buyer offered?
McLerran & Associates has guided owners through roughly 2,000 successful practice sales and evaluated more than 10,000 practices over approximately 35 years. The firm works both transition paths, private-buyer and DSO, in roughly equal measure. Its sell-side-only mandate means its incentives align with the selling dentist, not the buyer.
Schedule a confidential call to explore your options before any DSO conversation goes further.
